Northstar neurostim depression study
This article was originally published in The Gray Sheet
Executive Summary
Northstar Neuroscience is enrolling patients in a cortical stimulation feasibility study for treatment-resistant depression following FDA go-ahead in August. At the Leerink Swann stroke devices roundtable in New York Oct. 4, CEO Alan Levy said the firm is motivated by the large market size for depression. The PROSPECT trial will enroll up to 12 patients at three sites. Northstar's implantable technology stimulates the outermost layer of the brain, the cortex, to encourage brain activity. According to the firm it is less invasive than other, deeper brain stimulations. Levy projects a 2008 PMA filing for the Northstar Stroke Recovery System for hand and arm rehabilitation in stroke victims (1"The Gray Sheet" July 31, 2006, p. 13)...